Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 443

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 443
---
 of March 31, 2025Maturity               (In Years)Amortized CostUnrealized GainsUnrealized LossesFair ValueMoney market funds$227,319 $— $— $227,319 U.S. government treasury billsLess than 11,517 — — 1,517 Corporate bondsLess than 11,975 1 — 1,976 Total $230,811 $1 $— $230,812 As of December 31, 2024Maturity               (In Years)Amortized CostUnrealized GainsUnrealized LossesFair ValueMoney market funds$27,485 $— $— $27,485 U.S. government treasury billsLess than 112,553 9 — 12,562 Commercial paperLess than 11,743 1 — 1,744 Corporate bondsLess than 14,256 5 — 4,261 Total $46,037 $15 $— $46,052 

14

5. Accrued Liabilities 

Details of accrued liabilities are presented as follows (in thousands):March 31,2025December 31,2024Accrued professional fees$4,952 $5,157 Accrued salaries and payroll639 2,681 Accrued restructuring charges1,134 1,333 Accrued bonus524 64 Accrued clinical1,252 977 Accrued contract manufacturing— 2,597 Accrued other - sales related— 1,188 Accrued other116 650 Total accrued liabilities$8,617 $14,647 

6. Operating Leases

In April 2019, the Company entered into a twenty-eight month facility lease agreement for office space in Pacific Palisades, California (the “Pacific Palisades Lease”). The Pacific Palisades Lease commenced on May 1, 2019, included four months of rent abatement and a rent escalation clause and was set to expire on August 31, 2021. In August 2021, the Company exercised its option to extend the term of the Pacific Palisades Lease for an additional three-year period and entered into an amendment to the lease agreement (the “Pacific Palisades Lease Amendment”). Pursuant to the Pacific Palisades Lease Amendment, the Company and